Rapport Therapeutics Announces Positive Topline Results from Phase 2 Trial of RAP-219 for Bipolar Mania

Rapport Therapeutics has reported positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania. The study demonstrated statistically significant improvement in manic symptoms with an encouraging tolerability profile. Clinical benefits were consistently observed across all measures, with the most significant improvements in symptoms often leading to hospitalization for acute mania patients.